Roche’s Inavolisib Receives Breakthrough Designation for Advanced Breast Cancer Treatment

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with pa...

May 21, 2024 | Tuesday | News
CancerVax, Inc. Achieves Precision Cancer Targeting Milestone with Nobel-Winning Chemistry

CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer,  announced that its UCLA res...

May 21, 2024 | Tuesday | News
AstraZeneca's Big Bet: $1.5 Billion Investment in State-of-the-Art Cancer Treatment Hub in Singapore

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC por...

May 20, 2024 | Monday | News
QIAGEN Clinical Insight Interpret Earns IVDR Certification for Oncology and Hereditary Applications

As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is appro...

May 16, 2024 | Thursday | News
Oncolytics Biotech® Teams Up with GCAR to Advance Adaptive Trial for Pancreatic Cancer Treatment

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOB...

May 15, 2024 | Wednesday | News
Photocure's Partner Asieris Pharmaceuticals Advances Cevira® for Potential Approval in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...

May 13, 2024 | Monday | News
Zai Lab's AUGTYRO™ Approved by NMPA in China for ROS1-Positive NSCLC Treatment

Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...

May 13, 2024 | Monday | News
Siren Biotech & Catalent Inc. Partner for Cancer Gene Therapy

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of bett...

May 09, 2024 | Thursday | News
CytomX Therapeutics Collaborates with MSD for First-in-Human Trial of Novel CX-801 Cytokine to Revolutionize Cancer Treatment

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...

May 08, 2024 | Wednesday | News
Novartis Fortifies RLT Pipeline with Mariana Oncology Acquisition

Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology ...

May 03, 2024 | Friday | News
Biomerica and UAE's Healthcare Giant Ink Pioneering Deal for Advanced Cancer Screening Technologies

Biomerica Inc. , a global leader in innovative medical diagnostics, proudly announces a landmark multi-year exclusive distribution agreement with one of th...

April 30, 2024 | Tuesday | News
Hyundai Bioscience Announces Clinical Development Plan for Oral Niclosamide Metabolic Anticancer Drug Targeting p53 Gene Mutations

Hyundai Bioscience announced its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cance...

April 25, 2024 | Thursday | News
Gain Therapeutics Reports Positive Results from Phase 1 Study of GT-02287, Showcasing Promising Safety and Tolerability Profile

Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...

April 25, 2024 | Thursday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close